The Netherlands Shells Out $350 To Speed Cancer Drug Development

Preclinical cancer drug development is a topline priority for the Netherlands, and the €325 million ($351 million) that it plans to funnel through the Dutch National Growth Fund (DNGF) will enable specialist capabilities to help biotechs accelerate oncology candidate development...